International application No.

PCT/JP2004/005456

			7012004/005450 .
A. CLASSIFIC Int.Cl	CATION OF SUBJECT MATTER A61K45/00, 38/00, 31/517, A6	1P27/02	
According to Int	ernational Patent Classification (IPC) or to both nation	al classification and IPC	
B. FIELDS SE			
Minimum docum	nentation searched (classification system followed by control A61K45/00, 38/00, 31/517, A6	lassification symbols) 1P27/02	·
	searched other than minimum documentation to the extended of t		
MEDLIN	E CAPLUS EMBASE BIOSIS(STN) JM	EDPLUS (JOIS)	
C. DOCUMEN	ITS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where a	opropriate, of the relevant passages	
X .	NEGISHI M. et al., 'Regulation formation by Rho family GTPa: Journal of Japanese Biochemic 2002 May; 74(5): 395-8. [Japa	ses.', Seikagaku. cal Society,	1-12
х	Nikolic M. 'The role of Rho of associated kinases in regular outgrowth.' Int J. Biochem Co 2002 July; 34(7): 731-45.	ting neurite	1-12
X	Lehmann M. et al., 'Inactivate signaling pathway promotes Claregeneration.' J Neurosci. 03 (01.09.99); 19(17): 7537-47.	NS axon	1-12,
× Further do	cuments are listed in the continuation of Box C.	See patent family annex.	
* Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is		"T" later document published after date and not in conflict with the the principle or theory underlying document of particular relevant considered novel or cannot be step when the document is take	ce; the claimed invention cannot be e considered to involve an inventive in alone
cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed		"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family	
Date of the actual completion of the international search 07 June, 2004 (07.06.04)		Date of mailing of the internation 22 June, 2004 (
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer	
Facsimile No. Form PCT/ISA/210	O (second sheet) (January 2004) ATTACHME	ENT F	

Form PCT/ISA/210 (continuation of cannot chast) (Innuan, 2004)

International application No. PCT/JP2004/005456

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT			
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
X	Dergham P. et al., 'Pho signaling pathway targeted to promote spinal cord repair.' J Neurosci. 01 August, 2002 (01.08.02): 22(15): 6570-7.	1-12	
x .	US 2002/0119140 A1 (Lisa McKerracher), 29 August, 2002 (29.08.02), Full text (Family: none)	1-12	
X	WO 02/083175 A1 (Senju Pharmaceutical Co., Ltd.), 24 October, 2002 (24.10.02), Full text & EP 1378247 A1	1-12	
x	WO 01/068607 Al (Mitsubishi Pharma Corp.), 20 September, 2001 (20.09.01), Full text & EP 1270570 Al	1-12	
х	<pre>JP 2003-073357 A (Mitsubishi Pharma Corp.), 12 March, 2003 (12.03.03), Full text (Family: none)</pre>	1-12	
Y	WO 02/076977 A2 (BAYER CORP.), 23 October, 2002 (23.10.02), Example 1 (Family: none)	1-12	
Y	WO 02/100833 Al (Sumitomo Pharmaceuticals Co., Ltd.), 19 December 2002 (19.12.02), Example 1 (Family: none)	1-12	
Y	JP 2000-044513 A (Santen Pharmaceutical Co., Ltd.), 15 February, 2000 (15.02.00), Par. No. [0024]; compound 3 & EP 1094055 A1	1-12	

International application No. PCT/JP2004/005456

Box No	. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)		
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons: 1. Claims Nos.: 13-16			
because they relate to subject matter not required to be searched by this Authority, namely: Claims 13 to 16 pertain to methods for treatment of the human body by therapy and thus relate to a subject matter which this International Searching Authority is not required, under the provisions of Article 17(2)(a)(i) of the PCT and Rule 39.1(iv) of the Regulations under the PCT, to search.			
2.	Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:		
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).		
Box No.	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)		
This Into	ernational Searching Authority found multiple inventions in this international application, as follows:		
1.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.		
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.		
3.	As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:		
4.	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:		
Remark	on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.		

International application No.

PCT/JP2004/005456

<Subject of search>

Claims 1 to 12 relate to a corneal neurite formation promoter, a corneal nerveaxon extension promoter, a corneal perception repairing agent and a remedy for dry eye each containing, as the active ingredient, a compound defined by a desired property as "an Rho protein inhibitor". Thus, claims 1 to 12 involve any compounds having this property in the scopes thereof. However, it is recognized that only small part of the claimed compounds are exclusively disclosed in the description in the meaning within PCT Article 5 and thus these claims are not supported by the disclosure in the description in the meaning within PCT Article 6.

Even though the common technical knowledge at the point of the application is taken into consideration, it cannot be recognized that the scope of compounds having the above property as "an Rho protein inhibitor" could be specified. Thus, claims 1 to 12 do not comply with the requirement of clearness as defined in PCT Article 6 too.

Therefore, the search was made on relationships among the inhibition of Rho protein and promotion of corneal neurite formation, promotion of corneal nerveaxon extension, repair of corneal perception and treatment for dry eye, as well as corneal neurite formation promoters, corneal nerveaxon extension promoters, corneal perception repairing agents and remedies for dry eye containing, as the active ingredient, the C3 enzyme and ROCK inhibitors of compounds 1 to 4 which are specifically illustrated in the description.